

## **SUVN-502 Study**

**A clinical research study to evaluate the added benefit of an investigational drug in people with moderate Alzheimer's disease who are currently taking stable doses of Donepezil and either Memantine or Namenda XR.**

SPRI Clinical Trials of Brooklyn, under the sponsorship of Suven Life Sciences, is currently participating in the clinical evaluation of the safety and effectiveness of an investigational drug in persons with moderate dementia due to Alzheimer's disease. At a minimum, to be eligible to participate in this clinical trial, you or someone you know must

- a) be between the ages of 50 and 85 years of age,
- b) have been diagnosed at least 1 year prior to study inception with moderate Alzheimer's disease,
- c) currently be on a stable dose of donepezil (10 mg) and Memantine (10 mg bid) or Namenda XR (28 mg qd), or Namzaric™ for at least the past 3 months,
- d) have a friend, family member or caregiver who has frequent contact with the participant and is willing to accompany the participant to all study-related visits, oversee the participant's compliance with taking the study medication and be able to inform on the participant's overall cognitive and functional status.

Study medication and all study-related exams, test, procedures will be provided at no cost to you or your insurance company, with the exception of Namenda XR® or Namzaric™.

SPRI Clinical Trials, LLC is located at 3044 Coney Island Avenue, Suite 201, Brooklyn, NY. To volunteer or learn more about participating in this clinical trial, please call SPRI at 718-616-2400.